Allarity Therapeutics, Inc. (NASDAQ:ALLR) Sees Significant Decrease in Short Interest

Allarity Therapeutics, Inc. (NASDAQ:ALLRGet Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 614,300 shares, a decrease of 5.9% from the February 29th total of 652,700 shares. Based on an average daily volume of 130,600 shares, the short-interest ratio is presently 4.7 days. Currently, 11.8% of the company’s stock are short sold.

Allarity Therapeutics Trading Down 8.2 %

Shares of Allarity Therapeutics stock opened at $0.24 on Wednesday. Allarity Therapeutics has a 12-month low of $0.24 and a 12-month high of $154.40. The business’s 50 day moving average is $0.39 and its 200-day moving average is $0.51.

Institutional Investors Weigh In On Allarity Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Renaissance Technologies LLC bought a new stake in Allarity Therapeutics in the 1st quarter valued at $233,000. Armistice Capital LLC bought a new stake in Allarity Therapeutics in the 3rd quarter valued at $195,000. Finally, Sabby Management LLC bought a new stake in Allarity Therapeutics in the 3rd quarter valued at $268,000. Institutional investors own 11.53% of the company’s stock.

Allarity Therapeutics Company Profile

(Get Free Report)

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.

Featured Articles

Receive News & Ratings for Allarity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allarity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.